Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-29
2005-03-29
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S308000, C530S322000, C530S333000, C530S402000, C530S421000, C424S278100
Reexamination Certificate
active
06872700
ABSTRACT:
Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5424286 (1995-06-01), Eng
patent: 5686511 (1997-11-01), Bobo
patent: 6051557 (2000-04-01), Drucker
patent: 6268343 (2001-07-01), Knudsen et al.
patent: 6376549 (2002-04-01), Fine et al.
patent: 723694 (1998-01-01), None
patent: 199731732 (1998-01-01), None
patent: WO 9507098 (1995-03-01), None
patent: WO 9746584 (1997-12-01), None
patent: WO 9805351 (1998-02-01), None
patent: WO 9830231 (1998-07-01), None
patent: WO9830231 (1998-07-01), None
patent: WO 9907404 (1999-02-01), None
patent: WO 9925727 (1999-05-01), None
patent: WO 9925728 (1999-05-01), None
patent: WO 9940788 (1999-08-01), None
patent: WO 0041546 (2000-07-01), None
patent: WO 0041548 (2000-07-01), None
Bloom, S. R. et al. (1987) “Glucagonoma syndrome” Am. J. Med. vol. 82, pp. 25-36.*
Parhes, D. G. et al. (2001) “Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro” Metabolis, vol. 50, p. 583-589.*
Drucker, D. J. (1998) “Glucagon-like peptides” Diabetes, vol. 47, pp. 159-169.*
Bloom, S. R. (1987) Glucagonoma syndrome. Am. J. Med. vol. 82(5B), pp. 25-36. Review.*
Carlsson, A. et al. (2000) Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA).□□J. Clin. Endocrinol. Metab. vol. 85, pp. 76-80.*
Marketletter, Aug. 24, 1998 (p. N/A).*
4, an Exendin-3 Analogue, fromHeloderma suspectumVenom,J. Biol. Chem.,267(11):7402-05 (1992).
Francis, et al., “PEGylation of Cytokines and Other Therapeutic Proteins and Peptides: the Importance of Biological Optimisation of Coupling Techniques,”International Journal of Hematology,68(1):1-18 (1998).
Goke, et al. “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells,”J. Biol. Chem.,268(26):19650-55 (1993).
Raufman, et al. “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem.,267(30):21432-37 (1992).
Chen, Y.E., et al., “Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard,”Journal of Biological Chemistry,272(7): 4108-4115 (1997).
Creutzfeldt, W.O.C., et al., “Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-like Peptide I(7-36) Amide in Type I Diabetic Patients,”Diabetes Care19(6):580-6 (1996).
D'Alessio, et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest.,97:133-38 (1996).
Eng, J., et al., “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem.,265(33):20259-62 (1990).
Thorens, “Expression Cloning of the Pancreatic β Cell Receptor for the Gluco-Incretin Hormone Glucagon-like Peptide 1,”Proc. Natl. Acad. Sci. USA,89:8641-45 (1992).
Byrne, M.M., et al., “Lessons from Human Studies with Glucagon-like Peptide-1: Potential of the Gut Hormone for Clinical Use,”Front. Diabetes,13:219-33 (1997).
Egan, J.M., et al., “Glucagon-like Peptide-1 Restores Acute Phase Insulin Release to Aged Rats,”Diabetologia,40(Supp 1):A130 abstract 505 (1997).
Daniel, O. et al., “Use of Glucagon in the Treatment of Acute Diverticultis,”British Medical Journal, 3:720-2, (1974).
Eissele, et al., “Rat Gastric Somatostation and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-like Peptide-1 (GLP-1) Amide,”Life Sci., 55(8):629-34 (1994).
Eng, J., “Prolonged Effect of Exendin-4 on Hyperglycemia of db/db mice,”Diabetes,45(Supp 2):152A (abstract 554) (1996).
Glauser, et al., “Intravenous Glucagon in the Management of Esophageal Food Obstruction,” JACEP, 8:228-231 (1979).
Malhotra, et al., “Exendin-4, a New Peptide fromHeloderma SuspectumVenom, Potentiates Cholecystokinin-Induced Amylase Release from Rat Pancreatic Acini,”Regulatory Peptides,41:149-56 (1992).
O'Halloran, et al., “Glucagon-like Peptide-1 (7-36)-NH2: A Physiological Inhibitor of Gastic Acid Secretion in Man,” J. Endocrinol. 126(1):169-73 (1990).
Ørskov, et al., “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable,”Diabetes42:658-61 (1993).
Passa, P., et al., “Mechanisms Suppressing Glucagon Secretion in Glucagonomas,”Diabetologia,19(3):305 [abstract 298 ] (1980).
Schepp, et al., “Exendin-4 and Exendin-(9-39)NH2: Agonist and Antagonist, Respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36)NH2,”Eur. J. Pharm.,269:183-91 (1994).
Schjoldager, et al., “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,”Dig. Dis. Sci.,34(5):703-8 (1989).
Singh, et al., “Use of125I-[Y39] exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastric Chief Cells from Guinea Pig,” Regul. Pep., 53:47-59 (1994).
Stower, et al., “A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease,”Br. J. Surg.,69:591-2 (1982).
Turton, M.D., et al., “A Role for Glucagon-like Peptide-1 in the Central Regulation of Feeding,”Nature,379:69-72 (1996).
Wettergren, et al., “Truncated GLP-1 (Proglucagon 78-107-Amide Inhibits Gastric and Pancreatic Functions in Man,”Dig. Dis. Sci.,38(4):665-73 (1993).
Willms et al., “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Mal: Effects of Exogenous Glucagon-Like Peptide-1 (GLF-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,”J. Clin. Endocrinol. Metab.,81(1):327-32 (1996).
Gedulin Bronislava
Young Andrew A.
Amylin Pharmaceuticals Inc.
Arnold & Porter LLP
LandOfFree
Methods for glucagon suppression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for glucagon suppression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for glucagon suppression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3434771